Observational studyArquivos de neuro-psiquiatria2026
Real-world experience with rituximab for multiple sclerosis treatment in a Brazilian tertiary center.
Observational study in Arquivos de neuro-psiquiatria, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rituximab, an anti-cluster of differentiation 20 (anti-CD20) monoclonal antibody, has been widely used off-label for multiple sclerosis (MS) treatment, demonstrating high effectiveness and a favorable safety profile. However, real-world data from Brazil, particularly within the public healthcare system, remain scarce. Objective: To assess the real-world effectiveness and safety of rituximab for MS treatment in a Brazilian tertiary center. Methods: We conducted a single-center, observational study at Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), including MS patients treated with rituximab between January 2016 and October 2024. The primary outcome was the change in annualized relapse rate (ARR) following rituximab initiation. The secondary outcomes included disability progression, radiological activity, and safety. The statistical analyses employed non-parametric tests and time-to-event analysis. Results: Among the 45 patients (25 with relapsing-remitting MS [RRMS], 18 with secondary progressive MS, and 2 with primary progressive MS), rituximab reduced the ARR by 89.8% (from 0.49-0.05; Conclusion: Rituximab demonstrated high effectiveness and acceptable safety for MS treatment in a Brazilian public healthcare setting. Its favorable risk-benefit profile supports broader adoption in resource-limited contexts.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.